Danish pharmaceutical giant Novo Nordisk announced Monday the US Food and Drug Administration (FDA) had approved its popular GLP-1 anti-obesity drug Wegovy to be administered in pill form for weight loss. “With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the…
World Health Organization Issues Guideline for Glucagon-like-Peptide-1 Therapies Use in Obesity: JAMA December 2025 Special Communication We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Drugmaker Cipla on Wednesday said it has launched a medication for managing obesity and type-2 diabetes mellitus. The company has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus, two of the country’s most pressing health challenges, the Mumbai-based drugmaker said in a regulatory filing. The company has the rights to…
From Launch to Leadership: Mounjaro Crosses Rs 333 Crore, Becomes India’s Top-Selling Drug We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eli Lilly‘s weight-loss therapy Mounjaro became India’s top-selling drug by value in October, data showed on Friday, overtaking GSK’s widely used antibiotic Augmentin, as demand surges in the world’s most populous nation. The U.S. drugmaker’s popular injectable therapy raked in 1 billion rupees ($11.38 million) in October, research firm Pharmarack said. That outpaced Augmentin sales…
Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link